spacer
home > ict > autumn 2017 > revolutionary potential
PUBLICATIONS
International Clinical Trials

Revolutionary Potential

For clinical research, the shift away from paper has been a
long and gradual process. Decades have now passed since
electronic data capture (EDC) was first implemented in a trial,
yet, to this day, some researchers remain beholden to paper
case report forms (CRFs) and databases. In fact, even those
who have switched are not fully electronic, as data is only
entered into the system after it is captured on a paper CRF at
the site level. In other words, while EDC has taken great strides
in modernising the operations of clinical data managers,
workflows at the site level are largely the same – as far as
data capture is concerned – as before the emergence of
eClinical technology.

This is one of the central reasons why the advent of eSource
technology – which allows data to be entered directly into
an electronic system and shared remotely with no paper
involved – represents a watershed moment for research.
eSource is largely seen as an improvement to timelines and
data integrity and, therefore, a boon for sponsors and CROs.
However, it is from these sites that these improvements
emanate.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Mike Novotny is founder and CEO at Medrio. He previously served as President of the EDC software company Ninaza before founding Medrio in 2005. Mike has 20 years of experience in research and software and holds a BA from Stanford University, US, and an MBA from Columbia University, US.

Nick O’Brien
is Marketing Copywriter at Medrio, where he writes the company blog as well as press releases and other copy. He has extensive experience writing for blogs and other media and holds a BA in English, with an emphasis on creative writing, from Kenyon College, US.
spacer
Mike Novotny
spacer
spacer
spacer
Nick O'Brien
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

PCI Pharma Services Announces Release of Joint White Paper with Domino on Ink Leachability in Pharmaceutical Serialization

Leading pharmaceutical outsourcing services provider PCI Pharma Services (PCI) has announced the release of a published white paper detailing Domino’s study which analyzes potential leachability of ink from coding technologies used in pharmaceutical Serialization activities. The study was executed to ensure no migration into drug product contained within HDPE bottles with directly applied codes. Domino is an industry leader in coding and printing technologies operating in over 120 countries worldwide, and one of the key providers of coding technologies to PCI across its global supply network.
More info >>

White Papers

Planning the Execution of a Viral Clearance Study

Eurofins BioPharma Product Testing

Viral clearance studies are a necessary component of any regulatory submission for clinical trials or commercial product approval for all biopharmaceutical products. These studies are performed to evaluate the capability of the purification process to remove or inactivate viruses that could potentially contaminate the starting material. They are complex studies that require substantial financial and personnel resources, as well as specialized scientific expertise to perform. As such, viral clearance studies are often performed at a qualified contract testing laboratory rather than in-house. When multiple parties are involved in this process, clear communication and a comprehensive understanding of the approach and timeline is critical.
More info >>

 
Industry Events

Pharma and Device Packaging and Labeling West Coast 2017

28-29 November 2017, Burlingame, California

Following a very successful launch year, we are thrilled to announce that Pharma and Device Packaging and Labeling will be returning to the West Coast for our 2nd annual event.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement